Global insulin market expected to reach $32.35 million in 2018, with China accounting for 10.2%

20 September 2012

The worldwide insulin market was worth nearly $12.48 billion in 2011 and is expected to reach USD almost $32.35 billion in 2018, growing at a compound annual growth rate (CAGR) of 12% from 2011 to 2018, according to a new market report published by Transparency Market Research.

Titled Insulin Market - Global and China Scenario, Trends, Industry Analysis, Size, Share and Forecast, 2011–2018, the report notes that, in the global market, China is expected to increase its share in the global insulin market to 10.2% by 2018.

The global insulin market is driven by rise in diabetic population worldwide. The world diabetes population was estimated at 366 million in the year 2011, and is expected to reach 552 million in 2030. It is estimated that diabetes accounts for 4.6 million deaths, with cases of people dying due to lack of insulin and not even being diagnosed.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Pharmaceutical